Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs Lumora

Kin Meds
Graded #73

Higher grade

vs+6.800000000000011
Lumora
Graded #205

Lower grade

The verdict

Kin Meds takes it — 72.9/100 to 66.1/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +38
74
36
Dose & formulationKin Meds +18
93
75
Clinical oversightLumora +13
74
87
Labs & monitoringLumora +23
53
76
FulfillmentLumora +2
72
74
Contract termsEven
55
55
Kin Meds · left barLumora · right bar

The numbers

MetricKin MedsLumora
WeighScore72.9/10066.1/100
GradeCC
Scorecard rank#73#205
Semaglutide$149/mo (brand Wegovy)$199/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$149/mo (brand Zepbound)$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
Lumora

Graded #205 · C

Strengths

  • Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
  • Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
  • LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
  • Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
  • Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141

Where it loses points

  • Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
  • Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
  • Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
  • No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
  • Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard